| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 10.6 | 72.4 |
| Profit before tax | -17.4 | -8.1 |
| Net income | -17.7 | -8.1 |
| EPS (diluted, $ a share) | $-0.07 | $-0.04 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -85.3% |
|---|---|
| Operating margin | -162.7% |
10-Q filed with the SEC, OTC: VXRT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Vaxart, Inc.: key numbers
- Share price
- $0.3600Close, Nov 16
- Market cap
- $87.7M
- Shares outstanding
- 243.7MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Vaxart, Inc.
All →Vaxart Financial Results
Vaxart reported third quarter 2026 financial results and provided a business update, highlighting $65.5 million in cash and a runway into Q2 2027. The company expects topline data from its Phase 2b COVID-19 trial, involving approximately 5,400 participants, by mid-year 2027. Additionally, Vaxart expanded its norovirus vaccine IP with a new European patent and appointed Retired Vice Admiral Raquel C. Bono to its Board of Directors.
“During the third quarter, the Vaxart team worked diligently to advance our Phase 2b COVID-19 trial. The release of the topline efficacy and safety data from the main cohort remains a top priority, and we continue to actively work toward completion of analytical testing and disclosure of the trial results, in collaboration with our partner BARDA.”
Steven Lo, Chief Executive Officer of Vaxart
Vaxart Leadership Change
Vaxart, Inc. appointed Raquel C. Bono, M.D., a retired U.S. Navy Vice Admiral and former Director of the Defense Health Agency, to its Board of Directors effective October 16, 2026. Dr. Bono will serve as Chair of the Stockholder Engagement Committee and was appointed pursuant to a cooperation agreement entered into with a group of stockholders in July 2026.
- Counterparty
- Raquel C. Bono
Vaxart Executive Compensation
Vaxart's Board of Directors approved a new Director Stock Ownership Policy requiring non-employee directors to hold stock valued at two times their annual cash retainer. The Board also adopted a Director Resignation Policy requiring directors to tender their resignation if they receive more 'withhold' than 'for' votes in an uncontested election.